Tom Powles (@tompowles1) 's Twitter Profile
Tom Powles

@tompowles1

Interested in Urology Cancers, biomarkers and drug development.

ID: 1206580727296544769

calendar_today16-12-2019 14:24:22

1,1K Tweet

12,12K Takipçi

62 Takip Edilen

Tom Powles (@tompowles1) 's Twitter Profile Photo
Tom Powles
@tompowles1

3 years ago

Cabozantinib/ipilimumab/nivolumab triplet hits DFS primary endpoint (vs ipi/nivo). RR 43% +CR 3% are modest. 32% increase in G3/4 toxicity may be explanation. Benefit seem ⬆️ in intermediate risk pts. OS is going to be important for things to significantly change #ESMO22

Cabozantinib/ipilimumab/nivolumab triplet hits DFS primary endpoint (vs ipi/nivo). RR 43% +CR 3% are modest. 32% increase in G3/4 toxicity may be explanation. Benefit seem ⬆️ in intermediate risk pts. OS is going to be important for things to significantly change #ESMO22